OncoMatch/Clinical Trials/NCT05592015
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Is NCT05592015 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Ruxolitinib for t-cell large granular lymphocyte leukemia.
Treatment: Ruxolitinib — This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Platelet count > 50 x 10^9/L (transfusion permitted if >50,000/uL within 5 days of last transfusion); ANC >= 100/mm^3 (G-CSF permitted if ANC remains above 100/mm^3 for 5 days after last growth-factor)
Kidney function
Serum creatinine <= 2 x ULN; eGFR >= 30 mL/min (MDRD equation); Platelets <100 x 10^9/L and renal impairment (CrCl < 90 mL/min) not permitted
Liver function
Total bilirubin <= 1.5 x ULN (patients with Gilbert's syndrome with a bilirubin > 1.5 x ULN permitted); AST and ALT <= 2.5 x ULN; ALP <= 2.5 x ULN
Platelet count > 50 x 10^9/L...Serum creatinine <= 2 x ULN...eGFR >= 30 mL/min...Total bilirubin <= 1.5 x ULN (patients with Gilbert's syndrome with a bilirubin > 1.5 x ULN permitted)...AST and ALT <= 2.5 x ULN...ALP <= 2.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify